The KDM4B antibody is a crucial tool in epigenetic research, targeting the lysine demethylase 4B (KDM4B/JMJD2B), a member of the Jumonji C domain-containing histone demethylase family. KDM4B specifically demethylates trimethylated histone H3 lysine 9 (H3K9me3) and lysine 36 (H3K36me3), modulating chromatin structure and gene expression. It plays pivotal roles in transcriptional regulation, DNA repair, cell cycle progression, and stem cell maintenance. Dysregulation of KDM4B is linked to cancers, developmental disorders, and metabolic diseases, as its overexpression can promote oncogenesis by activating hypoxia signaling, Wnt/β-catenin pathways, and genomic instability.
The KDM4B antibody is widely used to investigate its expression, subcellular localization, and interactions in various biological contexts. Researchers employ it in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study tissue-specific expression patterns or aberrant activity in tumors. It also aids in assessing the efficacy of KDM4B inhibitors in preclinical models, supporting drug development. Validated for specificity and sensitivity, this antibody helps unravel KDM4B's dual roles as both a transcriptional activator and repressor, depending on cellular context. Its utility extends to exploring KDM4B's involvement in epigenetic reprogramming, making it indispensable for studies in cancer biology, developmental biology, and therapeutic targeting of epigenetic enzymes.